- $99.29m
- -$120.71m
- $19.09m
Brief: Lenz Therapeutics Inc Files Of Mixed Shelf Offering Of Up To $500 Million - SEC Filing
Brief: Lenz Therapeutics Inc - Enters Sales Agreement With Td Cowen For $150 Million - SEC Filing
U.S. STOCKS ON THE MOVE-Accenture, Nike, FedEx
U.S. STOCKS ON THE MOVE-KKR, Micron Technology, Eli Lilly
U.S. STOCKS ON THE MOVE-Five Below, QXO, PDD Holdings
Citi ups PT on LENZ Therapeutics on eye-drop approval confidence
TD Cowen starts coverage of Lenz Therapeutics, sees derisked commercial story
U.S. RESEARCH ROUNDUP-American Electric Power, Block and Lenz Therapeutics
Brief: Corxel And Lenz Therapeutics Announce Positive Topline Data From China Phase 3 Presbyopia Trial Of Lnz100
Brief: LENZ Therapeutics Announces FDA Acceptance Of New Drug Application For LNZ100 For The Treatment Of Presbyopia
U.S. STOCKS ON THE MOVE-Identiv, Levi Strauss, cannabis firms
U.S. STOCKS ON THE MOVE-Spotify, Ulta Beauty, SPAR Group
Lenz Therapeutics gains as eye disease drugs succeed in late-stage trials
U.S. STOCKS ON THE MOVE-Lenz Therapeutics, Intel, ARCA Biopharma
Lenz Therapeutics gains as eye disease drugs succeed in late-stage trials
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study (updated)
Brief: Lenz Therapeutics Announces Positive Topline Data From Phase 3 Clarity Presbyopia Trials
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study
Brief: Ra Capital Management Lp Reports 16.6% Stake In Lenz Therapeutics As Of March 21 - SEC Filing